Playing the Drug-Development Game - Key technical considerations when developing a clinical project in the biotech world. - BioPharm International

ADVERTISEMENT

Playing the Drug-Development Game
Key technical considerations when developing a clinical project in the biotech world.


BioPharm International
Volume 25, Issue 3, pp. 66-67

Imagine a major game designer developing a new video game that is comprised of pitfalls and complexities so numerous and difficult that few players reach the midpoint, let alone complete the game successfully. This situation is analogous to the world of biotechnology, where companies face this scenario regularly and must do everything possible to increase their odds of successfully completing the "development game" and to reduce the risks of elimination. The risks and rewards of playing the game are high but few can afford to fail, even once.

Biotechnology projects are complex and subject to many levels of risk during the early clinical phases. Few products enter Phase III, and fewer still make it through approval and on to commercial manufacture. Furthermore, globalization and other recent developments, such as tighter quality control criteria, evolving technologies, and the increasing stringency of regulatory standards, have imposed enormous pressures on an already difficult task of taking a product to market.

The primary concern in most instances is to maximize the value of the compound in the earliest stages of development to assist in attracting investors, provide outlicensing opportunities or in some cases, allow outright acquisition by a larger company. To such companies, little thought is given to later development or the commercialization efforts that must be applied to the compound or the myriad of interfaces between various partners that might be necessary as they move forward with a project.

FINDING THE RIGHT ANSWERS

In clinical development, finding answers—the right answers—is anything but simple. There are many questions, many unexpected challenges, and many decisions that all need to be carefully and thoughtfully addressed because of their potential impact on the product's success.

Successfully conducting a clinical development project requires a biotech company to:

  • Ensure packaging material compatibility
  • Develop novel, efficient process solutions
  • Solve lyophilization problems, if relevant
  • Ensure consistent batch quality
  • Meet crucial deadlines for clinical trials
  • Expedite regulatory approvals
  • Streamline scale-up to commercial manufacturing.

This article focuses on a few of these steps.

PACKAGING REQUIREMENTS

Finding the right solution to specific problem starts with a clear understanding of a compound's underlying technical and scientific requirements. Compounds are becoming more complex and that means greater demands on primary packaging. Highly sensitive drugs, including biopharmaceutical ones, require optimally designed drug-delivery systems. In addition to technical challenges, there are growing cost pressures and increasingly strict rules from regulatory agencies. Therefore, drug manufacturers need a great deal of competence when calibrating packaging with the drug product. On one hand, there is the compound itself and its environmental conditions (e.g., reaction with certain materials, biological specifications). On the other hand, time factors (e.g., time-to-market) and long-term market success (e.g., product life-cycle management) are important criteria to consider.

Among other things, companies must ask—and answer—the following questions:

  • Is the drug product compatible with rubber stoppers, closure systems, and other related components?
  • How much silicon can the substance endure?
  • How can the silicon be applied to the interior panels of the system (e.g., spray siliconization or baked silicon)?
  • What materials are suited for the components (e.g., rubber formulation)?
  • Do the components have to be pretreated (e.g., teflon-coated stoppers)?
  • How is the substance's break-loose and glide force behavior?
  • What materials are compatible for add-on systems, such as safety devices?
  • What washing procedures are necessary?
  • How should sterilization be performed?


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
FDA Releases REMS Report
September 25, 2014
Author Guidelines
Source: BioPharm International,
Click here